MLLT11

Summary

MLLT11 (MLLT11 transcription factor 7 cofactor, HGNC:16997) is a protein-coding gene on chromosome 1q21.3, encoding Protein AF1q (Q13015). Cofactor for the transcription factor TCF7.

The gene variously symbolized ALL1, HRX, or MLL located on 11q23 has been demonstrated to be fused with a number of translocation partners in cases of leukemia. t(1;11)(q21;q23) translocations that fused the MLL gene to a gene on chromosomal band 1q21 in 2 infants with acute myelomonocytic leukemia have been demonstrated. The N-terminal portion of the MLL gene is critical for leukemogenesis in translocations involving band 11q23. This gene encodes 90 amino acids. It was found to be highly expressed in the thymus but not in peripheral lymphoid tissues. In contrast to its restricted distribution in normal hematopoietic tissue, this gene was expressed in all leukemic cell lines tested.

Source: NCBI Gene 10962 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 10 total
• MANE Select transcript: NM_006818

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16997
Approved symbol	MLLT11
Name	MLLT11 transcription factor 7 cofactor
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	AF1Q
Ensembl gene	ENSG00000213190
Ensembl biotype	protein_coding
OMIM	604684
Entrez	10962

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000368921, ENST00000889973, ENST00000889974, ENST00000889975, ENST00000889976, ENST00000919078, ENST00000919079, ENST00000919080

RefSeq mRNA: 1 — MANE Select: NM_006818 NM_006818

CCDS: CCDS982

Canonical transcript exons

ENST00000368921 — 2 exons

Exon	Start	End
ENSE00001448288	151067219	151069544
ENSE00001448289	151060397	151060553

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 99.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.1305 / max 2364.1979, expressed in 1635 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5189	41.0834	1479
5190	7.0102	845
5188	2.3863	936
5187	2.3436	845
5184	2.0344	858
5192	1.2057	332
5191	1.0868	361
5185	0.9845	447
5186	0.5263	298
5193	0.2654	110

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pons	UBERON:0000988	99.73	gold quality
middle temporal gyrus	UBERON:0002771	99.73	gold quality
frontal pole	UBERON:0002795	99.68	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.62	gold quality
orbitofrontal cortex	UBERON:0004167	99.54	gold quality
cerebellar vermis	UBERON:0004720	99.52	gold quality
Brodmann (1909) area 10	UBERON:0013541	99.52	gold quality
cortical plate	UBERON:0005343	99.50	gold quality
ganglionic eminence	UBERON:0004023	99.45	gold quality
superior vestibular nucleus	UBERON:0007227	99.40	gold quality
endothelial cell	CL:0000115	99.38	gold quality
dorsal root ganglion	UBERON:0000044	99.38	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.36	gold quality
superior frontal gyrus	UBERON:0002661	99.29	gold quality
paraflocculus	UBERON:0005351	99.23	gold quality
parietal lobe	UBERON:0001872	99.21	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.21	gold quality
substantia nigra pars compacta	UBERON:0001965	99.19	gold quality
postcentral gyrus	UBERON:0002581	99.15	gold quality
entorhinal cortex	UBERON:0002728	98.99	gold quality
occipital lobe	UBERON:0002021	98.69	gold quality
CA1 field of hippocampus	UBERON:0003881	98.69	gold quality
oocyte	CL:0000023	98.63	gold quality
ventral tegmental area	UBERON:0002691	98.57	gold quality
primary visual cortex	UBERON:0002436	98.50	gold quality
medulla oblongata	UBERON:0001896	98.49	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	98.42	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.40	gold quality
embryo	UBERON:0000922	98.24	gold quality
secondary oocyte	CL:0000655	98.22	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-MTAB-6911	yes	4557.74
E-HCAD-5	yes	2523.84
E-MTAB-10485	yes	2211.11
E-GEOD-75140	yes	2051.54
E-MTAB-9906	yes	1838.82
E-MTAB-11121	yes	1575.32
E-MTAB-6108	yes	1573.38
E-MTAB-10018	yes	650.24
E-MTAB-8205	yes	485.43
E-MTAB-3929	yes	81.23
E-MTAB-7316	yes	15.13
E-HCAD-25	yes	11.50
E-HCAD-10	yes	5.64
E-GEOD-93593	no	3860.72
E-MTAB-9154	no	3678.08

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
BAD	Activation

miRNA regulators (miRDB)

92 targeting MLLT11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-587	99.64	70.86	2611

Literature-anchored findings (GeneRIF, showing 22)

• The ectopic expression of human AF1q triggered the expression of the neuronal marker TuJ1 in non-neuronal human embryonic kidney (HEK) cells. (PMID:15530661)
• overexpression of AF1Q leads to more progression in human breast cancer (PMID:17929166)
• The study provides the first evidence that AF1q plays a critical role in the regulation of apoptosis and drug resistance. (PMID:18852119)
• high AF1q expression is a poor prognostic marker for adult patients with normal cytogenetics acute myeloid leukemia (PMID:19396856)
• AF1q up-regulation of BAD is through its effect on NF-kappaB and this may hint of its oncogenic mechanism in cancer. (PMID:20596645)
• Using in vitro assays based on either forced expression or shRNA-mediated silencing of AF1q, the study provides evidence that the protein promotes T- over B-cell differentiation in multipotent hematopoietic progenitors. (PMID:21715312)
• AF1q plays a role in the onset of basal apoptosis in ovarian cancer cells, thus providing new information about the activity of this protein whose biologic functions are mostly unknown (PMID:22761939)
• AF1Q had a KFERQ-like motif. (PMID:24880125)
• Findings indicate that breast cancer cells with a hyperactive AF1q/TCF7/CD44 regulatory axis in the primary sites may represent “metastatic founder cells” which have invasive properties. (PMID:26079538)
• Results demonstrate that AF1q gene transcription is regulated by REST through direct binding at -383 to -363 bp of AF1q promoter. (PMID:26341630)
• Data show that MLLT11/AF1q-induced PDGFR signaling enhanced STAT3 activity through Src kinase activation. (PMID:27259262)
• This finding suggested statistically significant role of interaction of TXNIP and AF1q polymorphisms (TXNIP-rs2236566, TXNIP-rs7211, and AF1q-rs2769605) in schizophrenia susceptibility. (PMID:27510506)
• These results suggest that AF1q would have a role as an enhancer in generation of stem-like population through activation of Wnt signaling pathway. (PMID:28188793)
• AF1q was significantly lower in borderline ovarian tumors (i.e., tumors of low malignant potential without stromal invasion) than in invasive tumors, thus corroborating the association between high AF1q expression and increased migratory/invasive cell behavior and confirming its potential role in ovarian cancer progression. (PMID:28423573)
• AF1q was up-regulated in human colorectal cancer tissues, and that this up-regulation was associated with tumor metastasis. AF1q contributes to CRC tumorigenesis through the activation of the AKT signaling pathway. (PMID:28475127)
• A positive correlation between AF1q and CD44 expression. (PMID:30154435)
• AF1q Expression Associates with CD44 and STAT3 and Impairs Overall Survival in Adenoid Cystic Carcinoma of the Head and Neck. (PMID:31273546)
• High AF1q expression is associated with Esophageal Cancer. (PMID:31671695)
• LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11. (PMID:32964980)
• A Monoallelic Variant in REST Is Associated with Non-Syndromic Autosomal Dominant Hearing Impairment in a South African Family. (PMID:34828371)
• MLLT11 siRNA Inhibits the Migration and Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells. (PMID:38075552)
• MLLT11 Regulates Endometrial Stroma Cell Adhesion, Proliferation and Survival in Ectopic Lesions of Women with Advanced Endometriosis. (PMID:38203610)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mllt11	ENSDARG00000071026
mus_musculus	Mllt11	ENSMUSG00000053192
rattus_norvegicus	Mllt11	ENSRNOG00000021110

Protein

Protein identifiers

Protein AF1q — Q13015 (reviewed: Q13015)

All UniProt accessions (2): Q13015, Q6FGF7

UniProt curated annotations — full annotation on UniProt →

Function. Cofactor for the transcription factor TCF7. Involved in regulation of lymphoid development by driving multipotent hematopoietic progenitor cells towards a T cell fate.

Subunit / interactions. Interacts with HSPA8 and LAMP2 isoform A; the interaction may target MLLT11 for degradation via chaperone-mediated autophagy. Interacts with TCF7.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome.

Tissue specificity. Expressed in myoepithelial cells of normal breast tissue (at protein level). Highly expressed in thymus. Expressed in colon, small intestine, prostate and ovary. Not detected in peripheral blood lymphocytes and spleen.

Post-translational modifications. Ubiquitinated, leading to degradation.

Disease relevance. A chromosomal aberration involving MLLT11 is found in acute leukemias. Translocation t(1;11)(q21;q23) with KMT2A/MLL1.

Similarity. Belongs to the MLLT11 family.

RefSeq proteins (1): NP_006809* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026778	MLLT11_fam	Family
IPR033461	WRNPLPNID	Domain

Pfam: PF15017

UniProt features (4 total): chain 1, short sequence motif 1, modified residue 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13015-F1	64.00	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 84

Mutagenesis-validated functional residues (1):

Position	Phenotype
24–32	constitutive nuclear sequestration.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 279 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, GNF2_RTN1, CREL_01, MODULE_52, GOBP_MEMBRANE_DEPOLARIZATION, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GCANCTGNY_MYOD_Q6, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, BOYAULT_LIVER_CANCER_SUBCLASS_G2, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_REGULATION_OF_MEMBRANE_DEPOLARIZATION, GOBP_POSITIVE_REGULATION_OF_MEMBRANE_DEPOLARIZATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, AATGGAG_MIR136

GO Biological Process (7): positive regulation of apoptotic process (GO:0043065), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of mitochondrial depolarization (GO:0051901), positive regulation of release of cytochrome c from mitochondria (GO:0090200), extrinsic apoptotic signaling pathway (GO:0097191), intrinsic apoptotic signaling pathway (GO:0097193), apoptotic signaling pathway (GO:0097190)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): nucleoplasm (GO:0005654), mitochondrion (GO:0005739), centrosome (GO:0005813), cytosol (GO:0005829), nucleus (GO:0005634), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
apoptotic process	2
apoptotic signaling pathway	2
cytoplasm	2
intracellular membrane-bounded organelle	2
regulation of apoptotic process	1
positive regulation of programmed cell death	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
mitochondrial depolarization	1
regulation of mitochondrial depolarization	1
positive regulation of membrane depolarization	1
release of cytochrome c from mitochondria	1
positive regulation of organelle organization	1
regulation of release of cytochrome c from mitochondria	1
cell surface receptor signaling pathway	1
intracellular signal transduction	1
signal transduction	1
binding	1
nuclear lumen	1
centriole	1
microtubule organizing center	1
intracellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

518 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MLLT11	KMT2A	Q03164	859
MLLT11	AFF1	P51825	654
MLLT11	MLLT6	P55198	621
MLLT11	MLLT10	P55197	600
MLLT11	ELL	P55199	596
MLLT11	MLLT1	Q03111	575
MLLT11	MLLT3	P42568	569
MLLT11	TCF7	P36402	521
MLLT11	SEPTIN6	Q14141	506
MLLT11	AFDN	P55196	505
MLLT11	ABI1	Q8IZP0	489
MLLT11	TXNIP	Q9H3M7	453
MLLT11	LEF1	Q9UJU2	432
MLLT11	CTNNB1	P35222	408
MLLT11	MLF1	P58340	396

IntAct

43 interactions, top by confidence:

A	B	Type	Score
DNAJA4	DNAJA2	psi-mi:“MI:0914”(association)	0.710
MLLT11	S100B	psi-mi:“MI:0915”(physical association)	0.590
MLLT11	TCF7	psi-mi:“MI:0915”(physical association)	0.510
HBZ	MLLT11	psi-mi:“MI:0915”(physical association)	0.490
MLLT11	HBZ	psi-mi:“MI:0915”(physical association)	0.490
	MLLT11	psi-mi:“MI:0915”(physical association)	0.400
TRIL	MLLT11	psi-mi:“MI:0915”(physical association)	0.400
MLLT11	LEF1	psi-mi:“MI:0915”(physical association)	0.370
MLLT11	FXR1	psi-mi:“MI:0915”(physical association)	0.370
MLLT11	HOXA1	psi-mi:“MI:0915”(physical association)	0.370
ECE1	MLLT11	psi-mi:“MI:0915”(physical association)	0.370
HSPA8	PPP6C	psi-mi:“MI:0914”(association)	0.350
ECH1	MCRIP1	psi-mi:“MI:0914”(association)	0.350
ECH1	A2ML1	psi-mi:“MI:0914”(association)	0.350
MAD2L2		psi-mi:“MI:0914”(association)	0.350
	TSPO	psi-mi:“MI:0914”(association)	0.350
DND1	RPSA2	psi-mi:“MI:0914”(association)	0.350
BCL2L14		psi-mi:“MI:0914”(association)	0.350
OASL	LARP1	psi-mi:“MI:0914”(association)	0.350
P2RY6	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC15A3		psi-mi:“MI:0914”(association)	0.350
P2RY6	RAVER1	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
Vav2	CALU	psi-mi:“MI:0914”(association)	0.350
ECT2L	NEFL	psi-mi:“MI:0914”(association)	0.350
RIOX1	NDUFS7	psi-mi:“MI:0914”(association)	0.350

BioGRID (82): MLLT11 (Affinity Capture-MS), S100B (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Synthetic Lethality), MLLT11 (Proximity Label-MS), MLLT11 (Co-fractionation), MLLT11 (Co-fractionation), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS), MLLT11 (Affinity Capture-MS)

ESM2 similar proteins: A1CMP1, A3KQS5, A5HWA8, A6R5Z3, E7Q3U9, O13709, O60071, O74986, O84008, O84512, O84640, O94670, O94707, P0C755, P22469, P25049, P34518, P35198, P39424, P40380, P41993, P97783, Q06324, Q07541, Q09383, Q09599, Q09664, Q0ULD0, Q0VCT1, Q13015, Q1DI23, Q4KMC9, Q5M971, Q5R4W2, Q6CQB7, Q6CS73, Q6FWU4, Q6ZQV5, Q722M0, Q7VKZ7

Diamond homologs: A3KQS5, P97783, Q0VCT1, Q13015, Q5M971, Q5R4W2

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
MLLT11	up-regulates	Proliferation
MLLT11	up-regulates	Differentiation
MLLT11	“up-regulates activity”	TCF7	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

10 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1031 predictions. Top by Δscore:

Variant	Effect	Δscore
1:151067255:T:TA	donor_gain	0.9900
1:151067267:T:TA	acceptor_gain	0.9900
1:151057932:G:GG	donor_gain	0.9800
1:151057908:G:T	donor_gain	0.9700
1:151057928:GTCA:G	donor_gain	0.9700
1:151063964:C:CC	acceptor_gain	0.9700
1:151067217:A:AG	acceptor_gain	0.9700
1:151067218:G:GG	acceptor_gain	0.9700
1:151067218:GGAA:G	acceptor_gain	0.9700
1:151067268:G:A	acceptor_gain	0.9700
1:151057881:G:GT	donor_gain	0.9600
1:151057885:C:G	donor_gain	0.9500
1:151067213:TTCTA:T	acceptor_loss	0.9500
1:151067214:TCTAG:T	acceptor_loss	0.9500
1:151067215:CTAGG:C	acceptor_loss	0.9500
1:151067216:TAG:T	acceptor_loss	0.9500
1:151057936:G:GG	donor_gain	0.9400
1:151058274:A:T	donor_gain	0.9400
1:151067206:GGTTT:G	acceptor_loss	0.9400
1:151067207:GTTT:G	acceptor_loss	0.9400
1:151067208:TTTC:T	acceptor_loss	0.9400
1:151067209:TTCT:T	acceptor_loss	0.9400
1:151067210:TCTTT:T	acceptor_loss	0.9400
1:151067211:CTTTC:C	acceptor_loss	0.9400
1:151067212:TTTCT:T	acceptor_loss	0.9400
1:151058273:G:GT	donor_gain	0.9300
1:151067267:TGGAG:T	acceptor_gain	0.9100
1:151067268:GGAGG:G	acceptor_gain	0.9100
1:151057930:C:A	donor_gain	0.9000
1:151059473:CCTCA:C	donor_loss	0.9000

AlphaMissense

597 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:151067258:T:C	F12L	0.993
1:151067260:T:A	F12L	0.993
1:151067260:T:G	F12L	0.993
1:151067269:G:C	W15C	0.991
1:151067269:G:T	W15C	0.991
1:151067447:T:A	W75R	0.991
1:151067447:T:C	W75R	0.991
1:151067267:T:A	W15R	0.990
1:151067267:T:C	W15R	0.990
1:151067438:T:C	F72L	0.990
1:151067440:C:A	F72L	0.990
1:151067440:C:G	F72L	0.990
1:151067449:G:C	W75C	0.990
1:151067449:G:T	W75C	0.990
1:151067264:T:C	F14L	0.988
1:151067266:C:A	F14L	0.988
1:151067266:C:G	F14L	0.988
1:151067280:T:C	I19T	0.986
1:151067259:T:C	F12S	0.980
1:151067272:G:C	R16S	0.976
1:151067272:G:T	R16S	0.976
1:151067280:T:A	I19N	0.976
1:151067439:T:C	F72S	0.974
1:151067444:T:C	F74L	0.974
1:151067446:C:A	F74L	0.974
1:151067446:C:G	F74L	0.974
1:151067280:T:G	I19S	0.972
1:151067259:T:G	F12C	0.971
1:151067448:G:C	W75S	0.971
1:151067460:T:A	I79N	0.966

dbSNP variants (sampled 300 via entrez): RS1000140490 (1:151069110 C>T), RS1000561407 (1:151063834 G>C), RS1000745137 (1:151066553 G>C), RS1000895962 (1:151061342 C>T), RS1001036557 (1:151063647 G>A,C), RS1001236637 (1:151069429 T>G), RS1001518189 (1:151059272 C>A,T), RS1001569194 (1:151058874 G>A,C), RS1002064470 (1:151064271 G>A,C), RS1002351638 (1:151064532 A>G), RS1002738563 (1:151062022 GA>G), RS1002800576 (1:151068900 A>G), RS1002863352 (1:151059515 T>A), RS1002925465 (1:151066029 G>A), RS1003312019 (1:151063694 G>C)

Disease associations

OMIM: gene MIM:604684 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008839_497	Height	2.000000e-10
GCST010988_254	Adult body size	4.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

80 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	5
Benzo(a)pyrene	increases methylation, increases expression	4
Air Pollutants	decreases expression, increases abundance	3
Tretinoin	decreases expression, increases expression	3
Cyclosporine	affects expression, increases expression	3
cobaltous chloride	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tunicamycin	decreases expression	2
Cadmium Chloride	increases expression	2
Okadaic Acid	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
perfluorodecanesulfonic acid	increases expression	1
methylmercuric chloride	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases expression	1
lead acetate	increases expression	1
sodium arsenate	increases expression	1
thallium sulfate	increases expression	1
arsenite	affects expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
potassium chromate(VI)	decreases expression	1
ferrous chloride	increases expression	1
cupric chloride	increases expression	1
nickel sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
azoxystrobin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.